Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65

• Status: Terminated
• Trial end date: 2016-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out if by giving a combination of 3 drugs the leukemia will go into complete remission (meaning the leukemia is completely gone), and to find out how long it stays away. The drugs used in this project are FDA approved and commercially available.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Elizabeth Henry
• Treatments: Azacitidine; Cholecalciferol; Deferasirox; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• 65 or older (must have reached 65th birthday)

• Morphologically confirmed diagnosis of AML, excluding AML-M3

• Must have a Zubrod performance status of 0-3

Exclusion Criteria:

• Patients with known HIV infection are excluded. If HIV infection is suspected based on clinical condition, testing may be performed at the discretion of treatment team, but is not mandated prior to enrollment.

• Patients with central nervous system involvement by AML are excluded

• Patients with history of an active cancer (except basal cell and squamous cell cancers of the skin) within the previous 2 years are excluded